Reply to thread

Message: <blockquote data-quote="imhotep" data-source="post: 27059186" data-attributes="member: 562115">UK is the first country to approve Molnupiravir.The antiviral Lagevrio (Molnupiravir) is safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory Agency (MHRA) announced today.This follows a rigorous review of its safety, quality and effectiveness by the UK regulator and the government's independent expert scientific advisory body, the Commission on Human Medicines, making it the first oral antiviral for the treatment of COVID-19 to be approved.Developed by Ridgeback Biotherapeutics and Merck Sharp & Dohme (MSD), Lagevrio works by interfering with the virus' replication. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.Based on the clinical trial data, Lagevrio is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible following a positive COVID-19 test and within five days of symptoms onsetMolnupiravir has been authorised for use in people who have mild to moderate COVID-19 and at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.PS: There were several threads posted since it's development started and the most recent one<a href="https://elakiri.com/threads/molnupiravir-the-oral-antiviral-for-covid-licensing-concerns.2015961/" target="_blank">https://elakiri.com/threads/molnupiravir-the-oral-antiviral-for-covid-licensing-concerns.2015961/</a></blockquote>

Verification: Dahaya deken beduwama keeyada?

Top Bottom